(MedPage Today) — CHICAGO — Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA-mutated, endocrine-resistant disease…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115726
Author :
Publish date : 2025-05-22 21:00:00
Copyright for syndicated content belongs to the linked Source.
